Vanguard Personalized Indexing Management LLC Has $1.54 Million Holdings in Halozyme Therapeutics, Inc. $HALO

Key Points

• Vanguard Personalized Indexing Management LLC increased its holdings in Halozyme Therapeutics by 29.3%, owning 29,629 shares valued at approximately $1.54 million as per its latest SEC filing.
• Analysts have recently downgraded Halozyme's stock, with Zacks Research moving it from a "strong-buy" to a "hold" rating, and the company currently has a consensus rating of "Hold" with an average target price of $73.00.
• CEO Helen Torley sold 20,000 shares for about $1.5 million, a 2.65% reduction in her ownership, highlighting notable insider transactions amidst recent trading activity.

Vanguard Personalized Indexing Management LLC raised its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 29.3% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 29,629 shares of the biopharmaceutical company's stock after purchasing an additional 6,717 shares during the period. Vanguard Personalized Indexing Management LLC's holdings in Halozyme Therapeutics were worth $1,541,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Penserra Capital Management LLC acquired a new position in Halozyme Therapeutics during the 1st quarter valued at about $125,000. Bessemer Group Inc. raised its position in shares of Halozyme Therapeutics by 62.9% in the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 207 shares during the period. Redhawk Wealth Advisors Inc. raised its position in shares of Halozyme Therapeutics by 14.8% in the 2nd quarter. Redhawk Wealth Advisors Inc. now owns 37,419 shares of the biopharmaceutical company's stock valued at $1,947,000 after acquiring an additional 4,827 shares during the period. Intech Investment Management LLC raised its position in shares of Halozyme Therapeutics by 9.9% in the 1st quarter. Intech Investment Management LLC now owns 153,199 shares of the biopharmaceutical company's stock valued at $9,776,000 after acquiring an additional 13,789 shares during the period. Finally, GAMMA Investing LLC raised its position in shares of Halozyme Therapeutics by 199.0% in the 1st quarter. GAMMA Investing LLC now owns 2,802 shares of the biopharmaceutical company's stock valued at $179,000 after acquiring an additional 1,865 shares during the period. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

HALO has been the topic of a number of analyst reports. Zacks Research downgraded shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Monday, October 6th. Wall Street Zen downgraded shares of Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 5th. Leerink Partners upgraded shares of Halozyme Therapeutics from an "underperform" rating to a "market perform" rating and set a $70.00 price target on the stock in a research report on Tuesday. JPMorgan Chase & Co. increased their price target on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the company a "neutral" rating in a research report on Thursday, August 7th. Finally, Morgan Stanley raised their target price on shares of Halozyme Therapeutics from $75.00 to $80.00 and gave the stock an "overweight" rating in a report on Monday, August 18th. Five investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $73.00.

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the firm's stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $75.35, for a total transaction of $1,507,000.00. Following the completion of the transaction, the chief executive officer directly owned 733,719 shares of the company's stock, valued at $55,285,726.65. This trade represents a 2.65% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bernadette Connaughton sold 4,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $73.68, for a total transaction of $294,720.00. Following the transaction, the director directly owned 46,952 shares of the company's stock, valued at $3,459,423.36. This represents a 7.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 108,227 shares of company stock valued at $7,779,595 in the last ninety days. 2.40% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $67.03 on Friday. The company has a debt-to-equity ratio of 4.54, a quick ratio of 7.01 and a current ratio of 8.36. The company has a market capitalization of $7.84 billion, a P/E ratio of 15.34, a price-to-earnings-growth ratio of 0.36 and a beta of 1.16. The company's 50 day moving average price is $71.56 and its two-hundred day moving average price is $62.10. Halozyme Therapeutics, Inc. has a 52 week low of $42.01 and a 52 week high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.31. The company had revenue of $325.72 million during the quarter, compared to analysts' expectations of $282.66 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The business's quarterly revenue was up 40.8% on a year-over-year basis. During the same period last year, the business earned $0.91 EPS. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. On average, analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.